received by the International Bureau on 23 July 2019 (23.07.2019)

WHAT IS CLAIMED:

1. A method for the treatment of cancer in a patient, the method comprises a vaccination of the patient with a vaccine, wherein the vaccine comprises an effective amount of mammalian pluripotent stem cells obtained by reprogramming of somatic cells from the patient, wherein the vaccination comprising the step of administering mammalian pluripotent stem cells to the patient in need thereof.

2. The method of Claim 1 wherein the pluripotent stem cells are induced pluripotent stem cells (iPSCs).

3. The method of Claim 1 or 2, wherein the mammalian pluripotent stem cells are undifferentiated pluripotent stem cells.

4. The method of any one of Claims 1 to 3, wherein the pluripotent stem cells are generated using a mini-intronic plasmid containing four reprogramming factors comprising Oct4, c-Myc, KLF-4 and Sox2, with the possible addition of shRNA pS3.

5. The method of any one of Claims 1 to 4, wherein the stem cells are selected from the group consisting of fibroblast, keratinocytes, peripheral blood cells and renal epithelial cells.

6. The method of any one of Claims 1 to 5, wherein the adjuvant is an immunological agent to boost the immune response towards the vaccine.

7. The method of any one of Claims I to 6, wherein the vaccine is administered according to at least one of the following methods: a) as a standalone vaccination; b) as an adjuvant therapy before tumor resection; c) as an adjuvant therapy after tumor resection, d) in a metastatic setting; e) as a preventative setting in the absence of tumor or cancer; and 1) in combination with chemotherapy, immunotherapy, targeted therapies, using biologic agents, using small molecule agents, with nanoparticles comprising the biologic or small molecule agents, or a combination thereof.

8. The method of any one of Claims I to 7, wherein the cancer is selected from the group consisting of breast cancer, melanoma and mesothelioma.

9. The method of any one of Claims I to 7, wherein the cancer is selected from the group consisting of leukemia, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, lymphoma, myeloproliferative disorders, squamous cell cancer, adenocarcinoma, sarcoma, neuroendocrine carcinoma, bladder cancer, skin cancer, brain and spinal cord cancers, head and neck cancer, thyroid, bone cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastrointestinal cancers, (hypo)laryngeal cancer, esophageal cancer, liver cancer, lung cancer, pancreatic cancer, prostate cancer, eye cancer, renal cell cancer, kidney, hepatic, ovarian cancer, gastric cancer, testicular cancer, thyroid and thymus cancer.

10. A method for the vaccination of a mammal with a pluripotent stem cell cancer vaccine, die method comprising:

introducing the mammalian pluripotent stem cells by reprogramming from a somatic cell from the recipient; and

providing the recipient with pluripotent stem cells.

11. The method of Claim 10, wherein the mammalian cells are undifferentiated pluripotent cells.

12. The method of Claim 11 , wherein the pluripotent stem cells are generated using a mini-intronic plasmid containing four reprogramming factors comprising Oct4, c-Myc, KLF- 4 and Sox2.

13. The method of any one of Claims 10 to 12, wherein the pluripotent stem cells are selected from the group consisting of fibroblast, kcratinocytes, peripheral blood cells and renal epithelial cells.

14. The method of any one of Claims 10 to 13, wherein the vaccine is irradiated prior to vaccination.

15. The method of any one o f Claims 10 to 14, wherein the vaccine further comprises an adjuvant that is an immunological agent to boost the immune response towards the vaccine.

16. A thermally stable vaccine composition comprising an effective amount of mammalian pluripotent stem cells obtained by reprogramming of somatic cells from a mammalian, and an adjuvant or an immunological agent to boost the immune response towards the vaccine.

17. The vaccine composition of Claim 16, wherein the pluripotent stem cells are induced pluripotent stem cells (iPSCs).

18. The vaccine composition of Claim 16 or 17, wherein the mammalian pluri potent stem cells are undifferentiated pluripotent stem cells.

19. The vaccine composition of any one of Claims 16 to 18, wherein the stem cells are selected from the group consisting of fibroblast, keratinocytes, peripheral blood cells and renal epithelial cells.

20. The vaccine composition of any one of Claims 16 to 19, wherein the adjuvant is selected from the group consisting of CpG,QS21, poly(di(carboxylatophenoxy)phosphazene; derivatives of lipopolysaccharides such as monophosphoryl lipid A, muramyl dipeptide (MDP; Ribi), threonyl-muramyl dipeptide (t-MDP; Ribi); OM-174; cholera toxin (CT), and Leishmania elongation factor.